OakChart

Polypid Ltd

PYPDHealthcare·Biotechnology·Israel·Micro·NASD·Nov 11 • 3:50 PM ET

6.49+0.18 (2.85%)
2026-11-11 21:50 CET
Market cap
128.17 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-31.50 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.48
P/E
-
Compare

Price

PYPD against its 20, 50 and 200-day averages
2050200beatmissearnings
4.005.006.007.001.1M2.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PYPDclose 6.4920-day 5.5250-day 5.32200-day 4.786.4952w high52w low

9.1% under the 52-week high of 7.14 on 11 Nov 2026. 52-week low 3.50 on 21 Nov 2025. Last 15 sessions, 45.1% high to low

Volume 3.48× normal · the line is the 50-bar volume average

Profile

PYPD
52-week range, 100% of the way up
3.506.48

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

Employees75
IPOJun 26, 2020
Beta1.40
ATR, 14d0.40
Rel volume3.48
Short float6.10%
Insider own63.91%
Inst own15.82%

Snapshot

6 groups

Valuation

Index-
Market Cap131.83M
Enterprise Value126.63M
Income-31.50M
Sales0.00M
Book/sh0.27
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees75
IPOJun 26, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B24.47
P/C19.47
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.14
Current Ratio1.35
Debt/Eq0.29
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.48
EPS next Y-1.02
EPS next Q-0.41
EPS this Y104.94%
EPS next Y-1083.23%
EPS next 5Y41.66%
EPS past 3/5Y-0.87% 14.14%
Sales past 3/5Y- -
EPS Y/Y TTM61.30%
Sales Y/Y TTM-
EPS Q/Q55.37%
Sales Q/Q-
EarningsNov 11 BMO
EPS/Sales Surpr.-126.28% 0.00%

Ownership

Insider Own63.91%
Insider Trans0.00%
Inst Own15.82%
Inst Trans5.48%
ROA-119.05%
ROE-243.59%
ROIC-555.57%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2017.50%
SMA5021.95%
SMA20035.75%
Trades-

Technical

Shs Outstand20.31M
Shs Float7.33M
Short Float6.10%
Short Ratio3.77
Short Interest0.45M
52W High6.48 0.15%
52W Low3.50 85.43%
Volatility8.49% 6.36%
ATR (14)0.40
RSI (14)72.80
Beta1.40
Rel Volume3.48
Avg Volume118.76K
Volume402,730

Performance

Perf Week11.51%
Perf Month32.99%
Perf Quarter35.77%
Perf Half Y53.79%
Perf YTD49.54%
Perf Year72.61%
Perf 3Y73.07%
Perf 5Y-97.20%
Perf 10Y-
Recom1.00
Target Price11.40
Prev Close6.31
Price6.49
Change %2.85%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Oct 27, 2026InitiatedOOppenheimerOutperform$10+54.1%
Jun 05, 2025InitiatedRRoth CapitalBuy$9+38.7%
Jun 02, 2025ResumedHH.C. WainwrightBuy$11+69.5%
Jan 28, 2025InitiatedRRodman & RenshawBuy$13+100.3%
Sep 14, 2021InitiatedJJMP SecuritiesMkt Outperform$14+115.7%
Jul 30, 2021InitiatedCCantor FitzgeraldOverweight$24+269.8%
Nov 24, 2020UpgradeRRaymond JamesOutperform → Strong Buy
Aug 10, 2020InitiatedAAlliance Global PartnersBuy$27+316.0%
Jul 21, 2020InitiatedRRaymond JamesOutperform$23+254.4%
Jul 21, 2020InitiatedBBMO Capital MarketsOutperform$30+362.2%

Peers

Mkt cap
TickerCompanyMkt cap
CRMDCorMedix Inc409.60M
HRTXHeron Therapeutics Inc68.29M
EPRXEupraxia Pharmaceuticals Inc539.26M
CTXRCitius Pharmaceuticals Inc13.34M
SPROSpero Therapeutics Inc59.69M
INVAInnoviva Inc1.34B
PCRXPacira BioSciences Inc1.46B
VANIVivani Medical Inc101.48M
OCULOcular Therapeutix Inc1.46B
ACXPAcurx Pharmaceuticals Inc5.78M

News

latest 14 of 100
  • PolyPid's Steep Miss Reflects Deferred Azurity Revenue Ahead Of The November 28 D-PLEX100 Decision (Earnings Whispers)
  • PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • PolyPid Nears a Potentially Transformative FDA Decision as It Advances Its Innovative Pipeline (NASDAQ: PYPD) (FinanceWire)
  • PolyPid's First Profitable Quarter Hinges On Azurity Cash As FDA Decision Looms (Earnings Whispers)
  • PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026 (GlobeNewswire)
  • PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix Based Product Candidate for the Treatment of Diabetic Foot Infections (GlobeNewswire)
  • PolyPid to Present D-PLEX100 Microbiology Data at IDWeek 2026 (GlobeNewswire)
  • PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 (GlobeNewswire)
  • What PolyPid's Bold Moves in Europe Could Mean for D-PLEX100's Global Potential (NASDAQ: PYPD) (FinanceWire)
  • European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX100 (GlobeNewswire)
  • PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization Opportunities (GlobeNewswire)
  • PolyPid Announces Participation in Upcoming Fall Investor Conferences (GlobeNewswire)
  • PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... (GuruFocus.com)
  • PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11-0.2400.9130.96030.0030.003
2026Q22026-08-12-0.350-0.378-0.3500.000.004
2026Q12026-05-13-0.350-0.433-0.3530.000.003
2025Q42026-02-11-0.410-0.330-0.4120.000.004
2025Q32025-11-12-0.370-0.523-0.3720.000.004
2025Q22025-08-13-0.780-0.548-0.7770.000.004
2025Q12025-05-14-0.700-0.820-0.7040.000.002
2024Q42025-02-12-1.130-0.924-1.1300.000.005
2024Q32024-11-13-1.220-1.003-1.2200.000.004
2024Q22024-08-14-1.250-1.300-1.2530.000.003
2024Q12024-05-08-1.370-1.413-1.3740.000.003
2023Q42024-02-14-3.970-3.583-3.8440.000.003
2023Q32023-11-08-3.400-4.160-3.3960.000.003
2023Q22023-08-09-3.900-9.210-0.1320.000.002
2023Q12023-05-10-8.400-7.791-0.2820.000.003
2022Q42023-02-08-9.600-12.360-0.3320.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-53.572-65.460-4.4790.000.00
2021FY-67.800-63.500-2.2760.000.00
2022FY-60.900-67.131-2.0360.000.00
2023FY-16.930-20.053-16.9930.000.00
2024FY-4.910-4.584-4.9080.000.00
2025FY-2.090-2.093-2.2600.000.00
2026FY-0.103--35.09
2027FY--1.016--9.67
2028FY--0.415--24.70
2029FY-0.750--64.80
2030FY-1.570--95.80

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-115003.050.0015.27
2026Q4S2026-10-265003.050.0015.27
2026Q4S2026-08-124000.000.000.00
2026Q4S2026-05-134000.000.000.00
2026Q4S2026-02-113000.000.000.00
2026Q4S2025-11-122000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4R2026-11-11100-0.29-0.29-0.29
2026Q4R2026-10-26100-0.29-0.29-0.29
2026Q4R2026-08-12110-0.29-0.29-0.29
2026Q4R2026-07-20101-0.32-0.32-0.32
2026Q4R2026-05-13100-0.25-0.25-0.25
2026Q4R2026-04-27100-0.25-0.25-0.25
2026Q4R2026-02-11110-0.25-0.25-0.25

Estimate history

EPS, annual-4.4480.007-1.002-4.479-2.276-2.036-16.993-4.908-2.09-1.4823
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.253-1.22-1.13-0.704-0.777-0.372-0.412-0.353-0.347
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual13.29613.29613.29618.49518.75719.8521.65410.19118.20420.312
Period201720182019202020212022202320242025MRQ
Shares, quarterly4.7976.80310.19110.19115.65410.19118.20419.17420.312
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.001.461.621.821.721.121.010.950.41
Gross Profit0.00-1.46-1.62-1.82-1.72-1.12-1.01-0.95-0.41
Selling, General and Administrative Excl. Other30.1431.5126.4121.0537.1742.0325.2617.6117.95
Research and Development23.3623.8122.8116.1527.9930.5516.9514.0812.55
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-30.14-32.97-28.03-22.87-38.89-43.15-26.27-18.56-18.36
Interest Expense-1.211.531.711.340.000.000.020.04
Unusual Expense0.000.510.00-0.200.000.0011.37-11.37-24.47
Net Income Before Taxes-31.55-34.16-28.98-23.80-39.43-42.60-36.87-6.915.92
Income Taxes-0.050.010.040.070.130.000.000.000.00
Consolidated Net Income-31.50-34.17-29.02-23.87-39.56-42.60-36.87-6.915.92
Net Income From Continuing Operations-31.50-34.17-29.02-23.87-39.56-42.60-36.87-6.915.92
Net Income-31.50-34.17-29.02-23.87-39.56-42.60-42.92-13.330.09
EPS (Recurring)-1.39-2.07-4.91-17.09-2.04-2.28-3.65-1.60-1.28
EPS (Basic, Before Extraordinaries)-1.48-2.09-4.91-16.99-2.04-2.28-4.48-1.000.01
EPS (Diluted)-1.48-2.09-4.91-16.99-2.04-2.28-4.48-1.000.01
EBITDA--31.51-26.41-21.05-37.17-42.03-25.26-17.61-17.95
Non-Operating Income (Expense)0.060.530.570.580.800.540.780.31-0.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-3.832.232.613.324.754.580.750.76
Shares Outstanding20.3118.2010.191.6519.8518.7618.4913.3013.30
Market Capitalization128.17128.1720.686.21411.293,229.885,492.945,498.37-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.001.460.000.000.000.000.00
Gross Profit0.000.00-1.460.000.000.000.000.00
Selling, General and Administrative Excl. Other7.857.767.077.469.407.588.227.39
Research and Development6.135.766.225.266.226.127.035.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.85-7.76-8.53-7.46-9.40-7.58-8.22-7.39
Interest Expense--0.02-0.520.680.290.35
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-7.84-7.73-8.55-7.43-9.92-8.26-8.51-7.74
Income Taxes0.010.00-0.080.020.050.010.010.02
Consolidated Net Income-7.85-7.73-8.47-7.45-9.98-8.27-8.52-7.76
Net Income From Continuing Operations-7.85-7.73-8.47-7.45-9.98-8.27-8.52-7.76
Net Income-7.85-7.73-8.47-7.45-9.98-8.27-8.52-7.76
EPS (Recurring)-0.35-0.35-0.41-0.37-0.78-0.70-1.13-1.22
EPS (Basic, Before Extraordinaries)-0.35-0.35-0.41-0.37-0.78-0.70-1.13-1.22
EPS (Diluted)-0.35-0.35-0.41-0.37-0.78-0.70-1.13-1.22
EBITDA---7.07-----7.39
Non-Operating Income (Expense)0.010.030.000.030.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense----1.74---
Shares Outstanding20.3119.1718.2010.1915.6510.1910.196.80
Market Capitalization128.1783.5868.9933.9935.9727.6220.6823.40

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments13.1315.815.6113.1132.6044.8726.987.5517.94
Short Term Receivables0.000.000.000.000.000.000.020.020.03
Inventories1.110.000.000.000.000.000.000.000.00
Other Current Assets0.990.760.461.092.212.330.400.460.76
Total Current Assets15.2316.576.0714.1934.8147.2027.408.0318.73
Net Property, Plant & Equipment6.778.379.2211.688.765.896.126.192.93
Total Investments and Advances0.000.000.000.000.240.200.200.220.00
Other Assets0.310.280.090.100.4222.560.030.041.33
Total Assets22.3125.2215.3725.9744.2375.8533.7514.4822.98
Short Term Debt Incl. Current Port. of LT Debt2.157.714.544.980.000.000.000.000.00
Accounts Payable2.862.410.771.144.140.970.000.000.00
Other Current Liabilities2.732.571.972.433.941.902.583.693.36
Total Current Liabilities7.7412.687.298.558.082.882.583.693.36
Long Term Debt0.651.917.248.750.000.000.000.000.00
Provision for Risks Charges0.000.000.000.170.200.190.250.230.00
Other Liabilities2.952.942.952.670.000.0012.2422.9348.28
Total Liabilities11.3317.5417.4720.148.283.0715.0726.8551.65
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00106.3169.3559.98
Common Equity10.977.68-2.105.8335.9672.78-87.63-81.71-88.65
Total Shareholders Equity10.977.68-2.105.8335.9672.7818.68-12.36-28.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity10.977.68-2.105.8335.9672.7818.68-12.36-28.66
Total Liabilities & Stockholders Equity22.3125.2215.3725.9744.2375.8533.7514.4822.98
Book Value Per Share0.600.75-1.270.291.923.94-6.59-6.15-6.67
Tangible Book Value Per Share0.600.75-1.270.291.923.94-6.59-6.15-6.67
Full-Time Employees75616260796958-60
Price to Book Ratio23.799.581.7835.7689.8275.4869.39--
Return on Assets-143.79-142.99-115.45-112.69-70.95-67.28-28.6331.58-258.11
Return on Equity-366.29-1,038.73-1,278.60-189.32-78.36-80.62-218.58--
Return on Invested Capital-294.05-302.47-464.30-271.38-118.47-50.66-36.96--
Quick Ratio1.821.310.831.664.3116.4110.622.185.57
Current Ratio1.971.310.831.664.3116.4110.622.185.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--34.17-29.02-23.87-39.56-42.60-36.87-6.915.92
Depreciation-1.461.621.821.721.121.010.950.41
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-5.583.524.924.604.7515.95-10.39-23.48
Funds from Operations--27.13-23.88-17.13-33.24-36.73-19.91-16.35-17.15
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--0.751.92-0.11-1.084.35-1.69-1.010.47
Cash from Operating Activities--27.88-21.96-17.24-34.32-32.39-21.60-17.36-16.68
Capital Expenditures--0.21-0.08-0.20-1.77-2.99-1.18-0.88-3.07
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments--6.49-0.254.0018.3439.89-39.59-22.6914.03
Purchase of Investments--26.22-21.35-18.60-0.00-39.59-22.690.00
Sale Or Maturity of Investments-19.7221.1022.6018.3439.89--14.03
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--6.70-0.333.8016.5836.90-40.77-23.5610.96
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Change in Capital Stock-32.6035.8612.725.121.0362.7737.659.39
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-32.6035.8612.725.121.0362.7737.659.39
Proceedsfrom Stock Options-0.000.0012.714.420.0062.7637.659.36
Issuance or Reduction of Debt, Net--6.38-3.32-2.6211.310.000.000.000.00
Change in Long Term Debt--6.38-3.32-2.6211.310.000.000.000.00
Issuance of Long Term Debt-0.000.000.0011.710.000.000.000.00
Reduction of Long Term Debt--6.38-3.32-2.62-0.400.000.000.000.00
Net Financing Active Other Cash Flow--0.86-0.13-0.130.000.000.000.000.00
Other Financing Activities Uses--0.86-0.13-0.130.000.000.000.000.00
Cash from Financing Activities-25.3732.429.9816.431.0362.7737.659.39
Net Change in Cash--9.2110.12-3.46-1.315.550.41-3.273.67
Free Cash Flow--28.09-22.04-17.43-36.08-35.38-22.77-18.24-19.75

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.7711.1013.1318.9829.648.20
Short Term Receivables0.000.000.000.000.000.00
Inventories1.361.111.110.000.000.00
Other Current Assets0.760.350.990.610.350.57
Total Current Assets8.8912.5615.2319.5829.998.77
Net Property, Plant & Equipment6.026.236.776.957.407.79
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.00-----
Other Assets0.330.370.310.300.300.28
Total Assets15.2319.1622.3126.8437.6916.85
Short Term Debt Incl. Current Port. of LT Debt1.291.962.153.517.627.40
Accounts Payable1.661.532.861.912.572.02
Other Current Liabilities3.653.552.732.212.972.97
Total Current Liabilities6.607.057.747.6213.1512.39
Long Term Debt0.280.380.650.831.051.43
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.962.952.953.023.002.95
Total Liabilities9.8510.3811.3311.4817.2116.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.398.7810.9715.3720.480.09
Total Shareholders Equity5.398.7810.9715.3720.480.09
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.398.7810.9715.3720.480.09
Total Liabilities & Stockholders Equity15.2319.1622.3126.8437.6916.85
Book Value Per Share0.270.460.601.511.310.01
Tangible Book Value Per Share0.270.460.601.511.310.01
Full-Time Employees--75---
Price to Book Ratio23.797.272.882.55418.253.59
Return on Assets-119.05-186.78-143.79-147.37-120.69-146.02
Return on Equity-243.59-758.61-366.29-390.53-312.77-853.05
Return on Invested Capital-138.43-84.34-72.92-46.01-46.34-547.19
Quick Ratio1.141.631.822.572.280.71
Current Ratio1.351.781.972.572.280.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.10%0.4M7.3M118.47K
2026-10-153.08%0.2M7.3M168.11K
2026-09-301.72%0.1M7.3M192.73K
2026-09-151.78%0.1M7.3M216.13K
2026-08-312.66%0.2M7.3M218.38K
2026-08-143.36%0.2M6.9M228.82K
2026-07-315.99%0.4M6.9M210.13K
2026-07-154.11%0.3M6.9M144.37K
2026-06-301.23%0.1M6.9M112.73K
2026-06-152.12%0.1M6.9M88.88K
2026-05-292.01%0.1M6.9M73.02K
2026-05-150.65%0.0M6.9M53.67K
2026-04-300.44%0.0M6.9M51.83K
2026-04-151.52%0.1M7.8M57.19K
2026-03-310.42%0.0M10.5M61.26K
2026-03-130.22%0.0M10.5M62.97K
2026-02-270.27%0.0M8.7M75.10K
2026-02-130.35%0.0M8.7M75.82K
2026-01-300.32%0.0M8.7M80.64K
2026-01-150.22%0.0M8.7M84.31K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.355.002.3010.52822.000.000.973-0.0140.001
call5.001.201.901.532.63160917.000.787-0.0530.003
call7.500.150.300.251.57238.0024.000.326-0.0330.004
call10.000.000.450.603.1299.000.000.280-0.0620.004
put2.500.000.050.007.0630.000.00-0.084-0.0570.002
put5.000.000.500.043.13344420.00-0.213-0.0520.003
put7.500.151.450.002.0630.000.00-0.672-0.0320.004
put10.002.004.500.004.7630.000.00-0.738-0.0570.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-06-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-10SEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-04SCHEDULE 13G/ASEC
2026-04-063Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-063Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-03-263Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC6.14%
Rosalind Advisors, Inc.2.04%
DAFNA Capital Management LLC1.09%
MORGAN STANLEY0.65%
RENAISSANCE TECHNOLOGIES LLC0.61%
MARSHALL WACE, LLP0.60%
ADAR1 Capital Management, LLC0.54%
SYMMETRY PEAK MANAGEMENT LLC0.53%
J. Goldman & Co LP0.52%
JANE STREET GROUP, LLC0.44%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND7.64%
VANGUARD DEVELOPED MARKETS INDEX FUND5.16%
THE CONTINENTAL SMALL COMPANY SERIES2.34%
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND2.02%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO2.00%
iShares MSCI EAFE Small-Cap ETF1.97%
iShares Core MSCI EAFE ETF1.44%
Schwab International Small-Cap Equity ETF0.51%
VANGUARD TOTAL WORLD STOCK INDEX FUND0.50%
International Vector Equity Portfolio0.48%

OakChart. PYPD. Cached 15 minutes.

Some panels did not load: insider.